While not reaching the levels of 2020 – the year COVID-19 became a top priority for life science sectors – the life science industry in Germany is still performing strongly. In 2021, it was second-highest in terms of private equity investment value since we started tracking the data. Germany has a strong focus on research and development, with 66% of German Biotechs categorized as R&D services companies. Alongside major global economies such as the USA and China, Germany counts as one of the most research-intensive economies.
Many thanks to our German partners BioDeutschland, BioNRW, BioRN, and GTAI/HEALTH MADE IN GERMANY, with whom we compiled this year’s report.